These results collectively show that Olaparib-mediated STAT3 activation leads to upregulation of STAT3-downstream tumorigenic gene expression in ovarian cancer cells with and without HRD. This evidence concerns the gene STAT3 and hypoparathyroidism-retardation-dysmorphism syndrome.